Literature DB >> 28242662

Nitrotriazole-Based Compounds as Antichagasic Agents in a Long-Treatment In Vivo Assay.

Maria V Papadopoulou1, William D Bloomer2, Howard S Rosenzweig3, Ana Lia Mazzeti4, Karolina Ribeiro Gonçalves4, Priscila Fagundes Mendes4, Maria Terezinha Bahia5.   

Abstract

3-Nitrotriazole-based compounds belonging to various chemical subclasses were found to be very effective against Chagas disease both in vitro and in vivo after a short administration schedule. In this study, five compounds with specific characteristics were selected to be administered for longer periods of time to mice infected with the virulent Trypanosoma cruzi Y strain to further evaluate their effectiveness as antichagasic agents and whether or not potential adverse effects occur. Benznidazole was included for comparison purposes. Complete parasitemia depletion, weight gain, 100% survival, and a lack of myocardial inflammation were observed with four of the compounds and benznidazole administered intraperitoneally at 15 or 20 mg/kg of body weight/day for 40 days. There was a significant reduction in the number of treatment days (number of doses) necessary to induce parasitemia suppression with all four compounds compared to that required with benznidazole. Partial cures were obtained with only one compound tested at 15 mg/kg/day and on the schedule mentioned above but not with benznidazole. Taken together, our data suggest that these compounds demonstrate potent trypanocidal activity comparable to or better than that of the reference drug, benznidazole, when they are administered at the same dose and on the same schedule.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  Chagas disease; benznidazole; long treatment; nitrotriazoles

Mesh:

Substances:

Year:  2017        PMID: 28242662      PMCID: PMC5404586          DOI: 10.1128/AAC.02717-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  29 in total

1.  Novel 3-nitro-1H-1,2,4-triazole-based amides and sulfonamides as potential antitrypanosomal agents.

Authors:  Maria V Papadopoulou; William D Bloomer; Howard S Rosenzweig; Eric Chatelain; Marcel Kaiser; Shane R Wilkinson; Caroline McKenzie; Jean-Robert Ioset
Journal:  J Med Chem       Date:  2012-05-23       Impact factor: 7.446

2.  VFV as a New Effective CYP51 Structure-Derived Drug Candidate for Chagas Disease and Visceral Leishmaniasis.

Authors:  Galina I Lepesheva; Tatiana Y Hargrove; Girish Rachakonda; Zdzislaw Wawrzak; Sébastien Pomel; Sandrine Cojean; Pius N Nde; W David Nes; Charles W Locuson; M Wade Calcutt; Michael R Waterman; J Scott Daniels; Philippe M Loiseau; Fernando Villalta
Journal:  J Infect Dis       Date:  2015-04-15       Impact factor: 5.226

3.  Novel 3-nitro-1H-1,2,4-triazole-based aliphatic and aromatic amines as anti-chagasic agents.

Authors:  Maria V Papadopoulou; Bernadette Bourdin Trunz; William D Bloomer; Caroline McKenzie; Shane R Wilkinson; Chaiya Prasittichai; Reto Brun; Marcel Kaiser; Els Torreele
Journal:  J Med Chem       Date:  2011-11-04       Impact factor: 7.446

4.  Antitrypanosomal lead discovery: identification of a ligand-efficient inhibitor of Trypanosoma cruzi CYP51 and parasite growth.

Authors:  Grasiella Andriani; Emanuele Amata; Joel Beatty; Zeke Clements; Brian J Coffey; Gilles Courtemanche; William Devine; Jessey Erath; Cristin E Juda; Zdzislaw Wawrzak; Jodianne T Wood; Galina I Lepesheva; Ana Rodriguez; Michael P Pollastri
Journal:  J Med Chem       Date:  2013-03-13       Impact factor: 7.446

5.  VNI cures acute and chronic experimental Chagas disease.

Authors:  Fernando Villalta; Mark C Dobish; Pius N Nde; Yulia Y Kleshchenko; Tatiana Y Hargrove; Candice A Johnson; Michael R Waterman; Jeffrey N Johnston; Galina I Lepesheva
Journal:  J Infect Dis       Date:  2013-01-31       Impact factor: 5.226

6.  Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease.

Authors:  L S Filardi; Z Brener
Journal:  Trans R Soc Trop Med Hyg       Date:  1987       Impact factor: 2.184

7.  Ergosterol biosynthesis and drug development for Chagas disease.

Authors:  Julio A Urbina
Journal:  Mem Inst Oswaldo Cruz       Date:  2009-07       Impact factor: 2.743

Review 8.  Current and developing therapeutic agents in the treatment of Chagas disease.

Authors:  Werner Apt
Journal:  Drug Des Devel Ther       Date:  2010-09-24       Impact factor: 4.162

9.  High-throughput decoding of antitrypanosomal drug efficacy and resistance.

Authors:  Sam Alsford; Sabine Eckert; Nicola Baker; Lucy Glover; Alejandro Sanchez-Flores; Ka Fai Leung; Daniel J Turner; Mark C Field; Matthew Berriman; David Horn
Journal:  Nature       Date:  2012-01-25       Impact factor: 49.962

10.  Nitrotriazole-based acetamides and propanamides with broad spectrum antitrypanosomal activity.

Authors:  Maria V Papadopoulou; William D Bloomer; Howard S Rosenzweig; Shane R Wilkinson; Joanna Szular; Marcel Kaiser
Journal:  Eur J Med Chem       Date:  2016-08-09       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.